Medical Advisor to the Board

We are delighted to welcome Dr Gary Deed to our Medical Advisor to the Board. His expertise and experience will be invaluable asset in planning and delivering ME Group Australia’s vision and aspirations.

Dr Deed has been a quiet yet powerful advocate for ME/CFS and related diseases. Over a decade, he contributed his time and expertise for advocacy interviews and government enquiries. He truly is an unsung hero to people with ME/CFS in Queensland, Australia.

He has been consistently caring for patients with complex disease with compassion and evidence. His long-term patients will agree with us that his care without stigma or judgement has enabled us to relieve from challenging symptoms and trust in healthcare.

Some of his significant contributions for Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS).


Dr Gary Deed is a general practitioner with a passionate interest in promoting quality patient care of diabetes and obesity in general practice through education, development of resources including guidelines, policy development, research and strategic collaboration.

He is the Chair of the Diabetes Specific Interest Network for the Royal Australian College of General Practitioners (RACGP). He is the editor for the General Practice management of type 2 diabetes guideline for the RACGP and remains a member of the ADS Clinical Guidelines/Standards Advisory Committee. He is an Adjunct Senior Research Fellow of Monash University and helps co-ordinates the NHMRC funded ‘STAREE’ Statins in Reducing Events in the Elderly trial. He is a co-investigator and has published peer reviewed journal articles in diabetes and is an editor for Diabetes Therapy and adviser/editor for Endocrinology Today.

Current Commitments

  • General practitioner Carindale, Brisbane Australia
  • Adjunct Senior Research Fellow Monash University
  • National Chair Diabetes Specific Interest Group – RACGP 2011 – present
  • Member of the ADS/ANZOS Committee for Australian Diabetes Management Algorithm 2019 – ongoing
  • Member of the ADS Clinical Guidelines/Standards Advisory Committee (CAC) ongoing
  • Member of the RACGP Expert Committee – Quality Care 2018 – ongoing
  • Editor of the RACGP/Diabetes Australia – General practice management of type 2 diabetes 2014- ongoing



• Sarris J, Kavanagh DJ, Deed G, Bone KM.
St. John’s wort and Kava in treating major depressive disorder with
comorbid anxiety: a randomised double-blind placebo-controlled
pilot trial.
Hum Psychopharmacol. 2009 Jan;24(1):41-8.

• Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G.
The Kava Anxiety Depression Spectrum Study (KADSS): a
randomized, placebo-controlled crossover trial using an aqueous
extract of Piper methysticum.
Psychopharmacology (Berl). 2009

• Evans C, Dunstan RH, Rothkirch T, Roberts TK, Reichelt KL, Cosford
R, Deed G, Ellis LB, Sparkes DL. Altered amino acid excretion in
children with autism.
Nutr Neurosci. 2008 Feb;11(1):9-17.

• Deed, G Chronic fatigue Syndrome – Ch 35 pp 707-720 in
Sarris J, Wardle J (Eds) Clinical Naturopathy: Evidence Based Case
Studies. Sydney: Elsevier 2010

• Deed, G, Audhem R, Barlow, J, Kilov, G, Leow, Phillips, P, Sharma, A GP Insulin Toolkit, A Guide for Australian GPs Part 1 Initiating Insulin. Diabetes Management Journal Vol 37 Nov 2011.

• Deed G, Barlow, J, Khuo I Early and tight glycaemic control–the key to managing Type 2 diabetes. Australian Family Physician –
September 2012

• Deed G, Barlow J, Kawol D et al. Diet and Diabetes. AFP vol 44, 5 pp 192-196. May 2015

• Deed G, Kilov G, Phillips P, et al. Peer-to-Peer, Interactive GP Education can Reduce Barriers to Best Practice in Diabetes Management. Diabetes Therapy. 2016;7(1):153-161. doi:10.1007/s13300-016-0156-0.

• Deed G. Preventing hospital admission for diabetes emergencies in general practice: problems and solutions. Diabetes Management Journal Vol 54 pp 20-23 March 2016.

• Deed G, Kilov G, Dunning T Cutfield R Overland J, Wu T “Use of 50/50 Premixed insulin Analogs in type 2 Diabetes: Systematic Review and Clinical Recommendations” Diabetes Therapies (2017) 8: 1295-1296

• D’Emden M, Amerena J, Deed G, Pollock C, Cooper M. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. Diabetes Research and Clinical Practice 136 ( 2018 ) 23-31

• Co-Editor of the ADS/RACGP – Position statement on “Management of Hyperglycaemic Emergencies in General Practice” 2018

• Deed G, Atherton J, d’Emden M, Rasalam, R, Sharma A, Sindone A. Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice? Diabetes Therapy 2019 Oct;10(5):1625-1643

• Deed, G., Rasalam,R., Khoo C., Dover T., Forgione N. Improving Type 2 Diabetes Management in General Practice Using a Second-Generation Basal Insulin Analogue Insulin Glargine 300 U/mL: A Practical Guide. Diabetes Ther. 2019 Oct 21

• Arentz, A., Hunter, J., Deed, G. Integrating Traditional and Complementary Medicine Recommendations into Clinical Practice Guidelines for People with Diabetes in Need of Palliative and End-of-Life Care: A Scoping Review. J Altern Complement Med. 2020 Jul;26(7):571-591

• Marson A., Raffoul N., Osman R., Deed G. Patients with type 2 diabetes and cardiovascular disease in primary care. Australian Journal for General Practitioners 2021 Vol. 50 Pages 238-245

• Rasalam, R., Atherton, J. J., Deed, G., Molloy-Bland, M., Cohen, N., & Sindone, A. Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. ESC Heart Failure, (2021). 8(5), 4093-4118.

• Deed, G. Sick days, type 2 diabetes and the GP. Endocrinology Today 2021; 10(3): 25-28

• Fong C., Alesi, S., Mousa,A., Moran, L., Deed G. et al. Efficacy and Safety of Nutrient Supplements for Glycaemic Control and Insulin Resistance in Type 2 Diabetes: An Umbrella Review and Hierarchical Evidence Synthesis. Nutrients. 2022 May 30;14(11):2295.

• Sasso M S,.Muraki K., Eaton-Finch N., Smith P., Lesslar O., Deed G., Marshall-Gradisnik S. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients. Mol Med. 2022 Aug 19;28(1):98

• Wong J., Wu T., Deed G. Type 2 diabetes in young adults. A management guide for GPs. Medicine Today. 2022 23(9): 14-20

• Monash University – FOReal programme – Post-marketing evaluation of FORXIGA in Australian Medical Practice 2013 -2015

AZ “Discover” trial – Combination therapy in diabetes 2015-2020

STAREE Trial – co-investigator. 2017 – ongoing. Monash University.

“Australian type 1 diabetes general population screening pilot” – co – investigator. 2021 – ongoing. Sydney University

• START TRIAL – co-investigator 2022- ongoing The George Institute Sydney.